# EDGAR Filing Document

**Accession Number:** 0000353278
**File Stem:** 0001171843-26-002719
**Filing Date:** 2026-4
**Character Count:** 5967
**Document Hash:** bdd5da70959a374b291570f1d0eb80d4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-002719.hdr.sgml**: 20260427

**ACCESSION NUMBER**: 0001171843-26-002719

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260427

**FILED AS OF DATE**: 20260427

**DATE AS OF CHANGE**: 20260427

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NOVO NORDISK A S
- **CENTRAL INDEX KEY:** 0000353278
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-82318
- **FILM NUMBER:** 26896504

**BUSINESS ADDRESS:**
- **STREET 1:** NOVO ALLE DK 2880
- **CITY:** BAGSVAERD DENMARK
- **STATE:** G7
- **ZIP:** 00000
- **BUSINESS PHONE:** 4544448888

**MAIL ADDRESS:**
- **STREET 1:** NOVO ALLE DK 2880
- **CITY:** BAGSVAERD DENMARK
- **STATE:** G7
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVO NORDISK A/S
- **DATE OF NAME CHANGE:** 19900807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVO INDUSTRI A S /DENMARK/
- **DATE OF NAME CHANGE:** 19890811

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

***________________***

**FORM 6-K**

***________________***

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

April 27, 2026

***________________***

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé 1**

**DK- 2880, Bagsvaerd**

**Denmark**

(Address of principal executive offices)

***________________***

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

![](logo.jpg)

![](ca.jpg)

**Novo Nordisk A/S – Share repurchase programme**

Bagsværd, Denmark, 27 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 4 February 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 4 February 2026 to 4 May 2026.

Since the announcement 20 April 2026, the following transactions have been made:

---

| | | | |
|:---|:---|:---|:---|
| | **Number of<br> B shares**  | **Average**<br> **purchase price** | **Transaction <br> value, DKK** |
| **Accumulated, last announcement**  | **12257992** |  | **3148710807** |
| 20 April 2026 | 230000 | 255.92 | 58861892 |
| 21 April 2026 | 230000 | 255.95 | 58868391 |
| 22 April 2026 | 230000 | 249.65 | 57420415 |
| 23 April 2026 | 230000 | 249.19 | 57313744 |
| 24 April 2026 | 230000 | 251.11 | 57755946 |
| **Accumulated under the programme**  | **13407992** |  | **3438931195** |

---

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 30,797,791 B shares of DKK 0.10 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 24 April 2026, Novo Nordisk has since 4 February 2026 repurchased a total 13,407,992 B shares at an average share price of DKK 256.48 per B share equal to a transaction value of DKK 3,438,931,195.

*Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.*

**Contacts for further information**

---

| | |
|:---|:---|
| **Media:** | **Liz Skrbkova (US)** |
| **Ambre James-Brown** | **+1 609 917 0632** |
| +45 3079 9289 | lzsk@novonordisk.com |
| globalmedia@novonordisk.com | globalmedia@novonordisk.com |
| **Investors:** |  |
| **Michael Novod** | **Jacob Martin Wiborg Rode** |
| +45 3075 6050 | +45 3075 5956 |
| nvno@novonordisk.com | jrde@novonordisk.com |
| **Max Ung** | **Sina Meyer** |
| +45 3077 6414 | +45 3079 6656 |
| mxun@novonordisk.com | azey@novonordisk.com |
| **Alex Bruce** | **Christoffer Sho Togo Tullin** |
| +45 34 44 26 13 | +45 3079 1471 |
| axeu@novonordisk.com | cftu@novonordisk.com |
| **Frederik Taylor Pitter** | **Mads Berner Bruun** |
| +1 609 613 0568 | +45 3075 2936 |
| fptr@novonordisk.com | mbbz@novonordisk.com |
| Company announcement No 28 | Company announcement No 28 |

---

Page 2 of 2

---

| | | | |
|:---|:---|:---|:---|
| **Novo Nordisk A/S**<br>Investor Relations | Novo Allé 1<br>2880 Bagsværd<br>Denmark | Telephone:<br>+45 4444 8888 | <br>www.novonordisk.com<br> CVR no: 24 25 67 90 |
|  |  |  | Company announcement No 28 / 2026 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: April 27, 2026 NOVO NORDISK A/S <u>Maziar Mike Doustdar</u> Chief Executive Officer